List of Excipients in Branded Drug PRIVIGEN

Privigen Excipient Strategy and Commercial Opportunities in Intravenous Immunoglobulin

Last updated: August 13, 2026

Privigen is a 10% intravenous immune globulin, or IVIG, manufactured by CSL Behring. Its excipient platform is built around L-proline, polysorbate 80, water for injection, and a low-pH formulation without sucrose or antimicrobial preservatives. The formulation creates commercial opportunities in high-purity excipients, protein-stabilization technologies, low-peroxide surfactants, container systems, analytical testing, and manufacturing services.

Privigen’s commercial protection is driven primarily by biologic manufacturing capability, donor-plasma supply, regulatory controls, process know-how, and quality systems. Conventional small-molecule patent and generic-entry analysis is less informative because Privigen is licensed as a biologic under a Biologics License Application, or BLA, rather than as a conventional Orange Book small molecule.

What excipients are used in Privigen?

Privigen contains human normal immunoglobulin at 100 mg/mL. The principal excipients are L-proline, polysorbate 80, and water for injection. The product is formulated at an acidic pH and does not contain sucrose or preservatives, according to the U.S. prescribing information.[1]

Component	Function in Privigen	Commercial relevance
Human normal immunoglobulin	Active biologic ingredient	Requires plasma sourcing, fractionation, viral clearance, and extensive release testing
L-proline	Stabilizer and protein-excipient system	Supports immunoglobulin solubility and aggregation control
Polysorbate 80	Surfactant	Reduces protein adsorption and interfacial stress during processing and storage
Water for injection	Vehicle	Must meet pharmaceutical-grade compendial and microbiological standards
No sucrose	Avoids a sugar-based stabilizer	Supports use in patients where renal-risk considerations influence IVIG selection
No preservative	Reduces preservative-related compatibility and tolerability concerns	Supports single-dose parenteral presentation

The product is supplied as a ready-to-use solution in multiple vial sizes. The label identifies Privigen as a clear or slightly opalescent, colorless to pale yellow solution with a pH of approximately 4.6 to 5.0.[1]

Why is L-proline important in Privigen?

L-proline functions as a protein stabilizer in the Privigen formulation. Amino-acid excipients can influence protein solubility, conformational stability, aggregation, and interaction with container surfaces. In an immunoglobulin product, those effects matter because the active ingredient is a heterogeneous mixture of antibodies rather than a single recombinant protein.

L-proline also gives Privigen a differentiated excipient profile compared with IVIG products that use sucrose, maltose, sorbitol, glycine, or other stabilizers. That distinction can affect prescribing decisions in patients with renal impairment or other risk factors associated with certain IVIG formulations.

For excipient suppliers, the opportunity is not limited to commodity L-proline. Pharmaceutical customers require controlled impurity profiles, validated production, microbiological control, traceability, and consistent lot performance. Suppliers able to provide compendial and regulatory documentation have a stronger position than suppliers competing only on price.

What is the role of polysorbate 80?

Polysorbate 80 protects immunoglobulin against adsorption and aggregation caused by contact with air-liquid interfaces, tubing, pumps, filters, and container surfaces. The excipient must perform consistently across manufacturing, filling, transportation, and clinical use.

Polysorbate 80 can degrade through hydrolysis and oxidation. Degradation may generate free fatty acids, peroxides, and other species that can affect protein quality. Oxidative impurities can also interact with sensitive amino-acid residues in proteins. This creates opportunities for:

• Low-peroxide polysorbate 80 grades.
• Tight control of fatty-acid composition.
• Improved peroxide and aldehyde testing.
• Stabilized surfactant concentrates.
• Alternative nonionic surfactants.
• Supply-chain monitoring for storage and transportation conditions.

The commercial value of a polysorbate supplier is therefore linked to lot-to-lot consistency and analytical capability. A lower-cost material that produces higher variability or requires additional incoming testing can be commercially inferior to a premium grade.

How does Privigen’s excipient strategy compare with competing IVIG products?

Privigen competes with IVIG products including Gamunex-C, Gammagard Liquid, Octagam, Flebogamma DIF, Panzyga, and Asceniv. Formulation differences are commercially important because they affect renal warnings, osmolality, infusion tolerability, storage, administration, and physician familiarity.

Product	Manufacturer	Representative stabilizer or excipient strategy	Key commercial distinction
Privigen	CSL Behring	L-proline and polysorbate 80; no sucrose	Low-pH, ready-to-use liquid formulation
Gamunex-C	Grifols	Glycine-based formulation; no sucrose	Broad IVIG and subcutaneous immunoglobulin franchise
Gammagard Liquid	Takeda	Glycine-based formulation	Liquid IVIG platform with multiple indications
Octagam	Octapharma	Maltose-containing formulation	Established global IVIG product
Flebogamma DIF	Grifols	Sorbitol-containing formulation	Broad geographic availability
Panzyga	Octapharma	Glycine-based formulation	Newer liquid IVIG competitor
Asceniv	ADMA Biologics	Glycine-containing formulation	Specific immunoglobulin positioning

Exact excipient composition and concentrations must be evaluated against current product labeling in each jurisdiction. Formulation comparisons should not be treated as interchangeable because stabilizer systems can alter renal warnings, osmolality, compatibility, and handling requirements.[1-7]

Why does a sucrose-free formulation matter commercially?

Sucrose-containing IVIG products have historically been associated with heightened renal-risk warnings, particularly in patients with pre-existing renal insufficiency, diabetes, age-related risk, volume depletion, or nephrotoxic drug exposure. Privigen’s sucrose-free formulation supports positioning in settings where clinicians prefer to avoid sucrose-containing products.

The absence of sucrose does not eliminate all IVIG-associated renal or thrombotic risks. It does, however, give CSL Behring a formulation-based commercial distinction. Hospitals may also consider product-specific warnings, osmolality, concentration, infusion rate, supply reliability, and payer contracts.

What commercial opportunities exist for Privigen-related excipients?

The largest opportunities are in specialized materials and services that reduce manufacturing risk or strengthen product differentiation.

Pharmaceutical-grade L-proline

Potential suppliers can compete through:

• Compendial-quality L-proline.
• Low levels of trace metals and reactive impurities.
• Validated microbial and endotoxin controls.
• Dual-source manufacturing.
• Regulatory support for global submissions.
• Long-term supply agreements with biologics manufacturers.

L-proline is unlikely to be a high-margin product when sold as a basic commodity. The stronger opportunity is a qualified, documented grade supported by change-control discipline and a regulatory package suitable for biologics manufacturing.

High-performance polysorbate 80

Polysorbate 80 is a more technically attractive opportunity because its degradation profile can affect biologic quality. Suppliers can differentiate through:

• Low peroxide specifications.
• Controlled hydrolysis.
• Consistent ester distribution.
• Improved storage stability.
• Container compatibility.
• High-sensitivity degradation assays.
• Lot-release and stability-support packages.

The most valuable commercial model may combine excipient supply with analytical services. A supplier that can identify surfactant degradation products, correlate them with protein aggregation, and support process validation has a stronger negotiating position than a raw-material vendor.

Alternative surfactants

Alternative surfactants such as poloxamers or newer recombinant-protein-compatible surfactants may offer technical advantages. A replacement would face a high regulatory burden because changes could affect:

• Immunoglobulin aggregation.
• Particle formation.
• Subvisible particles.
• Potency.
• Fc function.
• Complement activation.
• Container interaction.
• Stability under shipping stress.

For an established product such as Privigen, an excipient change would likely require extensive comparability work and regulatory interaction. The near-term commercial opportunity is therefore greater in improved polysorbate 80 grades than in direct substitution.

Container and delivery systems

Excipient strategy is linked to the primary container and administration set. Commercial opportunities include:

• Low-binding polymeric containers.
• Improved vial coatings.
• Low-extractable elastomer closures.
• Reduced silicone-oil exposure.
• Compatible transfer devices.
• In-line filtration systems.
• Single-use manufacturing components with lower protein adsorption.

These technologies can reduce product loss and protect quality during filling and administration. A container change still requires extractables and leachables testing, particulate evaluation, stability studies, and container-closure validation.

What FDA regulatory status does Privigen have?

Privigen is an FDA-approved immune globulin intravenous product licensed under BLA 125268. The U.S. label identifies indications including primary humoral immunodeficiency, chronic immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy, subject to the approved prescribing information.[1]

Regulatory issue	Privigen status
FDA pathway	Biologics License Application
Dosage form	Intravenous solution
Strength	10%, or 100 mg/mL immunoglobulin
Manufacturer	CSL Behring
Preservatives	None listed
Sucrose	Not used as the stabilizing excipient
Main formulation excipients	L-proline and polysorbate 80
Product category	Human plasma-derived biologic
Substitution pathway	Biosimilar or interchangeable-biologic framework, not conventional ANDA substitution

The principal regulatory risk for an excipient supplier is a material change that affects product quality attributes. FDA review can focus on raw-material controls, viral safety where relevant, adventitious-agent controls, process consistency, stability, and comparability.

What patents protect Privigen and when does it lose exclusivity?

Privigen does not have a conventional Orange Book patent-expiration profile comparable to a small-molecule drug. Human plasma-derived immunoglobulin is regulated as a biologic, and the key exclusivity questions involve BLA data exclusivity, biosimilar approval pathways, manufacturing patents, formulation patents, process know-how, and regulatory protections.

The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity from first licensure, subject to statutory rules and pediatric exclusivity. Privigen’s original U.S. licensure occurred more than 12 years ago, so statutory reference-product exclusivity is no longer the principal barrier to competition.[8]

Protection category	Relevance to Privigen
Orange Book listing	Generally not the primary framework for the BLA product
Small-molecule Paragraph IV challenge	Not the normal pathway
BLA data exclusivity	Original 12-year period has elapsed
Biosimilar competition	Legally possible under the BPCIA
Formulation patents	May protect specific excipient combinations, concentrations, containers, or stability attributes
Manufacturing patents	May protect fractionation, purification, viral clearance, or filling processes
Trade secrets	Likely important for process parameters, specifications, and quality controls
Plasma supply	Major practical barrier that is not solved by patent expiry

A public, definitive list of Privigen-specific formulation and manufacturing patents requires a current patent-family search across CSL Behring entities, national filings, continuations, and terminal disclaimers. Patent risk should not be assessed solely through the FDA label or Orange Book.

Which companies could challenge Privigen?

Potential competition comes from established IVIG manufacturers rather than conventional generic-drug companies. Relevant competitors include Takeda, Grifols, Octapharma, Kedrion, ADMA Biologics, and other plasma-derived-product manufacturers.

A biosimilar or follow-on immunoglobulin developer would need to address:

• Donor-plasma supply.
• Fractionation and purification.
• Viral inactivation and removal.
• Antibody subclass distribution.
• Aggregate and particle control.
• Potency and functional assays.
• Clinical or comparative evidence.
• Manufacturing scale.
• Hospital contracting and distribution.

The regulatory challenge is substantial because immunoglobulin products are complex mixtures with clinically relevant heterogeneity. A competitor may achieve approval without duplicating every manufacturing step, but it must demonstrate a sufficiently comparable product under the applicable FDA pathway.

What formulation patents and manufacturing barriers matter most?

Formulation patents may cover a particular combination of L-proline, polysorbate 80, pH, protein concentration, osmolality, and storage conditions. Other claims may focus on reduced aggregation, reduced particulate formation, extended shelf life, or compatibility with a particular container.

Manufacturing patents may address:

• Plasma fractionation.
• Chromatographic purification.
• Viral clearance.
• Low-pH treatment.
• Nanofiltration.
• Removal of IgA or other impurities.
• Stabilization during concentration.
• Aseptic filling.
• Container closure.

Trade secrets may be more important than issued patents in areas such as process windows, resin selection, hold times, filter performance, and release specifications. These barriers can delay market entry even after formal patent protection expires.

What litigation and Paragraph IV risks affect Privigen?

Privigen is not principally exposed to conventional Paragraph IV litigation because it is a BLA biologic rather than an ANDA-listed small molecule. Competitive disputes would more likely involve BPCIA patent-exchange procedures, patent infringement actions, licensing arrangements, regulatory disputes, or commercial contracting.

A challenger could target patents relating to formulation, purification, viral clearance, container systems, or manufacturing methods. The practical litigation risk depends on claim scope, patent-family continuity, geographic coverage, and whether a noninfringing process can produce a comparable immunoglobulin.

No conclusion about current Privigen litigation or settlement agreements should be drawn from the absence of an Orange Book listing. BLA-related patent disputes may appear in federal court records, patent databases, or company disclosures rather than in the Orange Book.

How strong is the Privigen patent estate?

Privigen’s overall competitive position is stronger than a simple count of formulation patents would suggest. Its economic protection rests on several layers:

1. Plasma collection scale and donor access.
2. Manufacturing know-how.
3. Regulatory history and validated processes.
4. Product quality consistency.
5. Hospital supply contracts.
6. Brand recognition among immunologists and neurologists.
7. Formulation differentiation.
8. Potential process, formulation, and container patents.

The patent estate is likely strongest where claims cover non-obvious manufacturing steps or measurable stability improvements. Narrow claims limited to routine excipient substitutions may be easier to design around. Process patents can be commercially valuable, but enforcement may be difficult when a competitor’s process is conducted inside a confidential manufacturing facility.

What revenue exposure does Privigen create for CSL Behring?

CSL Behring reports commercial performance at broader business-segment levels, and public company disclosures generally do not isolate Privigen revenue with the precision needed for a product-level valuation. The relevant revenue drivers are IVIG demand, chronic inflammatory demyelinating polyneuropathy treatment, primary immunodeficiency, immunoglobulin supply constraints, price controls, payer contracting, and plasma-collection costs.[9]

Excipient supply disruptions could create disproportionate revenue exposure because a low-cost material such as L-proline or polysorbate 80 can become a critical-path input. Qualification of an alternate supplier may require comparability studies, stability data, manufacturing validation, and regulatory approval. The commercial value of dual sourcing is therefore high even when the excipient represents a small percentage of total product cost.

What generic launch scenarios exist for Privigen?

The most credible competitive scenarios are:

Scenario	Timing driver	Commercial impact
New branded IVIG entrant	Plasma supply and BLA approval	Increased contracting pressure
Biosimilar or follow-on immunoglobulin	Comparability package and manufacturing scale	Potential price competition
Formulation-improved IVIG	New excipient or delivery system	May compete on tolerability or convenience
Regional competitor	Local regulatory approval and plasma access	Greater geographic pressure
Capacity-led competition	New fractionation and filling plants	Supply expansion without direct patent challenge

A rapid generic-style launch is unlikely. IVIG competition depends on production capacity, plasma access, quality systems, and clinical acceptance. Excipient innovation can support product differentiation, but it is unlikely by itself to overcome the barriers associated with plasma-derived biologics.

What geographic opportunities exist for Privigen excipient suppliers?

The strongest geographic opportunities are in the United States, Europe, Japan, and markets with expanding immunoglobulin use. Regional suppliers can compete where they offer:

• Local regulatory support.
• Shorter lead times.
• Qualified backup capacity.
• Lower import exposure.
• Pharmacopeial compliance.
• Strong cold-chain and controlled-storage systems.
• Technical support for biologic manufacturers.

Global suppliers must manage differing pharmacopoeial expectations, excipient registration requirements, change-notification rules, and documentation standards. A supplier that qualifies material for one Privigen manufacturing site may still need separate technical and regulatory support for other sites.

Key Takeaways

• Privigen is a 10% human normal immunoglobulin containing L-proline, polysorbate 80, and water for injection.
• Its formulation is sucrose-free and preservative-free, creating a clinically relevant positioning advantage in selected IVIG patients.
• L-proline is a stabilizer; polysorbate 80 controls interfacial stress and protein adsorption.
• The strongest excipient opportunities are premium pharmaceutical-grade L-proline, low-peroxide polysorbate 80, surfactant analytics, and compatible container systems.
• Privigen is regulated under a BLA, so Orange Book and Paragraph IV analysis have limited direct application.
• The original biologic exclusivity period has elapsed, but biosimilar entry remains constrained by plasma supply, manufacturing complexity, comparability requirements, and commercial scale.
• Manufacturing know-how, quality systems, and supply reliability may provide more durable protection than formulation patents alone.
• Excipient suppliers can create strategic value by offering dual sourcing, regulatory documentation, degradation testing, and biologic-specific technical support.

FAQs about Privigen excipients and commercial strategy

Does Privigen contain sucrose?

No. Privigen uses L-proline as a principal stabilizing excipient and does not use sucrose as its formulation stabilizer.[1]

Is Privigen preservative-free?

Yes. The U.S. prescribing information identifies Privigen as a preservative-free intravenous immunoglobulin product.[1]

Can polysorbate 80 be replaced in Privigen?

Replacement is technically possible but would require extensive formulation development, analytical comparability, stability testing, process validation, and regulatory review. A replacement could affect aggregation, particles, potency, and container compatibility.

Is there a generic version of Privigen?

There is no conventional generic equivalent approved through the ANDA pathway. Competition would generally involve another licensed biologic, a biosimilar, or a follow-on immunoglobulin product.

What is the most attractive excipient opportunity linked to Privigen?

Low-peroxide, highly characterized polysorbate 80 is likely the most technically differentiated opportunity. Pharmaceutical-grade L-proline has a broader supplier base but can support attractive contracts when paired with strong documentation, dual sourcing, and biologics-focused quality services.

References

1. CSL Behring LLC. (2024). Privigen: Immune globulin intravenous (human), 10% liquid prescribing information. U.S. Food and Drug Administration.

2. Grifols Therapeutics LLC. (2023). Gamunex-C prescribing information. U.S. Food and Drug Administration.

3. Takeda Pharmaceuticals U.S.A., Inc. (2024). Gammagard Liquid prescribing information. U.S. Food and Drug Administration.

4. Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. (2024). Octagam 10% prescribing information. U.S. Food and Drug Administration.

5. Grifols Deutschland GmbH. (2023). Flebogamma DIF prescribing information. U.S. Food and Drug Administration.

6. Octapharma USA, Inc. (2024). Panzyga prescribing information. U.S. Food and Drug Administration.

7. ADMA Biologics, Inc. (2023). Asceniv prescribing information. U.S. Food and Drug Administration.

8. U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products. FDA.

9. CSL Limited. (2024). Annual report 2024. CSL Limited.